Petros Pharmaceuticals Inc Stock price
Is Petros Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.
Key metrics
Petros Pharmaceuticals Inc Stock Analysis
Analyst Opinions
7 Analysts have issued a Petros Pharmaceuticals Inc forecast:
Analyst Opinions
7 Analysts have issued a Petros Pharmaceuticals Inc forecast:
Don't miss a Thing! We will send you all news about Petros Pharmaceuticals Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Petros Pharmaceuticals, Inc. is a pharmaceutical company focused on men's health therapeutics. Its commercial capabilities include sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. The firm operates through Prescription Medications and Medical Devices segments. The Prescription Medications segment consists primarily of Stendra, which is sold generally in the United States. The Medical Devices segment includes vacuum erection devices, which are sold domestically and internationally. The company was founded on May 14, 2020 and is headquartered in New York, NY.
| Head office | United States |
| CEO | John Shulman |
| Employees | 18 |
| Website | www.petrospharma.com |


